Want to see AU:BIO full AI Analyst Report?
BIO Stock Chart & Stats
AU$0.40
-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.40
-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.20 - AU$0.63
Previous CloseN/A
Volume242.26K
Average Volume (3M)278.69K
Market Cap
AU$60.42M
Enterprise ValueAU$64.05M
Total Cash (Recent Filing)AU$3.36M
Total Debt (Recent Filing)AU$2.43M
Price to Earnings (P/E)61.6
Beta1.12
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding227,998,030
10 Day Avg. Volume235,222
30 Day Avg. Volume278,692
Financial Highlights & Ratios
PEG Ratio-4.04
Price to Book (P/B)21.27
Price to Sales (P/S)5.40
P/FCF Ratio-34.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$36.40M
Bulls Say, Bears Say
Bulls Say
Top-line GrowthConsistent revenue expansion at 16.14% demonstrates durable market traction for Biome's probiotic products. Sustained top-line growth supports investment in distribution and product development, helps achieve scale economics over time and reduces reliance on one-off items.
High Gross MarginA 61.12% gross margin indicates strong product-level pricing power or low direct costs, providing a structural buffer to absorb SG&A and enable reinvestment. High gross margins are a durable foundation for margin expansion as fixed costs are spread with growth.
Manageable Leverage And Solid Equity BaseModerate leverage (D/E 0.66) with a strong equity ratio and positive ROE implies financial flexibility and a resilient capital structure. This reduces refinancing risk, supports longer-term investment in channels and product development, and underpins stability through cycles.
Bears Say
Weak Cash ConversionNegative operating cash flow despite reported profits signals difficulty turning earnings into cash. This structural cash conversion weakness can force reliance on external funding, limit working capital for sales growth, and constrain sustained reinvestment over months.
Very Low Net ProfitabilityA net margin of ~1.17% and weak operating margins indicate limited retained profits per sale. Persistently thin profitability reduces the firm's ability to self-fund expansion, makes returns sensitive to cost inflation, and requires significant scale or margin improvement to be durable.
Small Operating ScaleA small workforce and modest scale can limit distribution reach, R&D capacity and operational redundancy. Structurally, this may slow market expansion, make execution riskier versus larger competitors, and constrain the company’s ability to scale margins reliably.
Biome Australia Ltd News
BIO FAQ
What was Biome Australia Ltd’s price range in the past 12 months?
Biome Australia Ltd lowest share price was AU$0.20 and its highest was AU$0.63 in the past 12 months.
What is Biome Australia Ltd’s market cap?
Biome Australia Ltd’s market cap is AU$60.42M.
When is Biome Australia Ltd’s upcoming earnings report date?
Biome Australia Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 61 days.
How were Biome Australia Ltd’s earnings last quarter?
Biome Australia Ltd released its earnings results on Feb 22, 2026. The company reported AU$0.005 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.001.
Is Biome Australia Ltd overvalued?
According to Wall Street analysts Biome Australia Ltd’s price is currently Undervalued.
Does Biome Australia Ltd pay dividends?
Biome Australia Ltd does not currently pay dividends.
What is Biome Australia Ltd’s EPS estimate?
Biome Australia Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biome Australia Ltd have?
Biome Australia Ltd has 227,998,030 shares outstanding.
What happened to Biome Australia Ltd’s price movement after its last earnings report?
Biome Australia Ltd reported an EPS of AU$0.005 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of Biome Australia Ltd?
Currently, no hedge funds are holding shares in AU:BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biome Australia Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (150.00% Upside)
AU$1.00 (150.00% Upside)
Blogger Sentiment
Bullish
AU:BIO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$146.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
17.85%
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Biome Australia Ltd
Biome Australia Limited, founded in 2018 and headquartered in Cremorne, Australia, specializes in the development, commercialization, and global distribution of live biotherapeutic and complementary health products. The company's product line features live biotherapeutics under the Activated Probiotics brand, organic nutritional supplements branded as Activated Nutrients, and athletic performance and recovery items named Activated X Performance. These offerings are accessible to consumers through both community pharmacies and independent health practitioners.
BIO Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(150.00% Upside)
Technical Analysis
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---